23andMe's president is stepping down

The president of 23andMe, a consumer genetics company, is
stepping down.

Andy Page, who has been at 23andMe since 2013, will remain on the
company's board, while all of his direct reports are going to
report to CEO Anne Wojcicki, according to a letter sent to
employees
obtained and first reported by Recode.

"Departing 23andMe is bittersweet for me," Page said in an
emailed statement to Business Insider. "On one hand, I will miss
the adventures of being with all of the teams day-to-day. On the
other hand, I am so pleased that I’ve been able to accomplish
what I was brought in to do. I take deep pride
in how far 23andMe has come in four short years, and that we are
at a stage of strength and maturity where Anne can take the sole
leadership role. It has been an incredible ride and I am looking
forward to remaining active on the board and assisting the
company however I can."

The news comes only a few weeks after
Buzzfeed reported that the company won't be pursuing
next-generation sequencing, a new, more expensive area of
genetic testing that companies have been adopting.

23andMe's chief medical officer Jill Hagenkord left the
company in October and is
now working at Color Genomics, a genetics testing company
that uses next-generation sequencing for its cancer screening
tests, under the same title.

In September, the company
also said that it would now offer two versions of the test,
including a $199 version, which comes with both the health
and ancestry components, and a $99 version, which will
just have the ancestry test.